Recurrent dysregulation associated with cis-regulatory mutations was also observed as exemplified in the promoter of BCL6 along with a potential cascading effect on interactors known to be involved in cancer development (Additional file 1: Figures S7 and S8 and Additional file 3). This evidence concerns the gene BCL6 and cancer.